Andre Moreira from the Universidade do Porto presents his research findings published in Allergy of a disproportionality analysis of the WHO's VigiBase pharmacovigilance database indicating a potential increased cancer risk with omalizumab:

Mota D, Rama TA, Severo M, Moreira A. Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database. Allergy. 2021; doi:10.1111/all.15008

Follow Allergy on:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]

Like, share and comment on our videos, thank you.
[ Ссылка ]

свернуть